OBJECTIVE: We evaluated the efficacy of a mucoadhesive vaginal gel (MVG, Miphil) with acidic-buffering properties in bacterial vaginosis (BV). STUDY DESIGN: Double-blind, placebo-controlled, 12-week trial. SUBJECTS: A total of 45 non-pregnant women with BV were enrolled in the trial. Patients were treated with MVG 2.5 g or the corresponding placebo (P) daily for the first week and then every 3 days for the following 5 weeks (treatment phase) in a 2:1 ratio. All patients were followed for an additional 6 weeks without treatments (follow-up phase). Clinical cure was defined as absence of vaginal discharge, vaginal pH <4.5, a negative fish odour test and a Nugent score <7. RESULTS: At week 6, 28 out of 30 women (93%) in the MVG group were clinically cured in comparison with only 1 out of 15 (6%) in the P group (P=0.0001). At week 12, 86% of MVG treated women remained cured in comparison with 8% in P group (P=0.0001). At baseline, the vaginal pH was 6.1+/-0.7 in the MVG and 5.5+/-0.7 in the P group. Vaginal pH significantly (P=0.003) decreased to 4.3+/-0.3 in the MVG group. In P group non-significant modifications of vaginal pH were observed (5.1+/-0.5). CONCLUSION: Our results demonstrated that this MVG is an effective treatment of BV.
RCT Entities:
OBJECTIVE: We evaluated the efficacy of a mucoadhesive vaginal gel (MVG, Miphil) with acidic-buffering properties in bacterial vaginosis (BV). STUDY DESIGN: Double-blind, placebo-controlled, 12-week trial. SUBJECTS: A total of 45 non-pregnant women with BV were enrolled in the trial. Patients were treated with MVG 2.5 g or the corresponding placebo (P) daily for the first week and then every 3 days for the following 5 weeks (treatment phase) in a 2:1 ratio. All patients were followed for an additional 6 weeks without treatments (follow-up phase). Clinical cure was defined as absence of vaginal discharge, vaginal pH <4.5, a negative fish odour test and a Nugent score <7. RESULTS: At week 6, 28 out of 30 women (93%) in the MVG group were clinically cured in comparison with only 1 out of 15 (6%) in the P group (P=0.0001). At week 12, 86% of MVG treated women remained cured in comparison with 8% in P group (P=0.0001). At baseline, the vaginal pH was 6.1+/-0.7 in the MVG and 5.5+/-0.7 in the P group. Vaginal pH significantly (P=0.003) decreased to 4.3+/-0.3 in the MVG group. In P group non-significant modifications of vaginal pH were observed (5.1+/-0.5). CONCLUSION: Our results demonstrated that this MVG is an effective treatment of BV.
Authors: Lindsay Armstrong-Buisseret; Clare Brittain; Miruna David; Gillian Dean; Frances Griffiths; Trish Hepburn; Louise Jackson; Joe Kai; Alan Montgomery; Tracy Roberts; Sukhwinder Thandi; Jonathan D C Ross Journal: Trials Date: 2019-11-27 Impact factor: 2.279
Authors: Ana Raquel Cunha; Rita M Machado; Ana Palmeira-de-Oliveira; José Martinez-de-Oliveira; José das Neves; Rita Palmeira-de-Oliveira Journal: Pharmaceutics Date: 2014-09-22 Impact factor: 6.321
Authors: Emilia Szymańska; Piotr Orłowski; Katarzyna Winnicka; Emilia Tomaszewska; Piotr Bąska; Grzegorz Celichowski; Jarosław Grobelny; Anna Basa; Małgorzata Krzyżowska Journal: Int J Mol Sci Date: 2018-01-28 Impact factor: 5.923